Use of a Foreign-sourced Reference Product as a Canadian Reference

From Health Canada


This guidance document provides the criteria for using a drug marketed in a country other than Canada as a Canadian Reference Product (CRP). This applies to

  • Abbreviated New Drug Submissions
  • Abbreviated Extraordinary Use New Drug Submissions

Who this guide is for

  • generic drug manufacturers

In this guide

1. Introduction

1.1 Policy Objectives

1.2 Policy Statements

1.3 Scope and Application

1.4 Background

2. Guidance for Implementation

3. Appendices

Appendix 1 - Determining Solubility

Appendix 2 - Calculation of Similarity Factor (f2)

View complete guide

Download PDF (264 KB, 14 pages)

Details and history

Published: November 24, 2017

Updated: July 12, 2018

Consulted: December 18, 2017

Part of topic(s): Guidance on legislation

Page details

Date modified: